Leniolisib

Chemical formula: C₂₁H₂₅F₃N₆O₂  Molecular mass: 450.199 g/mol  PubChem compound: 57495353

Therapeutic indications

Leniolisib is indicated for:

Activated phosphoinositide 3-kinase delta syndrome

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Leniolisib is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Leniolisib is contraindicated in the following cases:

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.